CAS Number101975-10-4
Synonyms3-[4-(difluoromethoxy)-3-methoxyphenyl]-1H-pyridazin-6-one; Zardaverine; 6-[4-(Difluoromethoxy)-3-methoxyphenyl]-3(2H)-pyridazinone; zardaverinum; zardaverina; 6-[4-(Difluoromethoxy)-3-methoxyphenyl]pyridazin-3(2H)-one
Molecular FormulaC12H10F2N2O3
Molecular Weight268.22
Purity98%
Density1.4±0.1 g/cm3
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 101975-10-4 |
| Catalog No. | 2A-9012984 |
| Chinese Name | 扎达维林 |
| Synonyms | 3-[4-(difluoromethoxy)-3-methoxyphenyl]-1H-pyridazin-6-one; Zardaverine; 6-[4-(Difluoromethoxy)-3-methoxyphenyl]-3(2H)-pyridazinone; zardaverinum; zardaverina; 6-[4-(Difluoromethoxy)-3-methoxyphenyl]pyridazin-3(2H)-one |
| Molecular Formula | C12H10F2N2O3 |
| Molecular Weight | 268.22 |
| Purity | 98 |
| Density | 1.4±0.1 g/cm3 |
| Storage Condition | 2-8℃ |
| Application | Zardaverine is a new PDE3 and 4 inhibitor with IC50 of 0.5 uM and 0.8 uM respectively. |
| PubChem ID | 24278784 |
| MDL Number | MFCD00867059 |
| SMILES | COc1cc(ccc1OC(F)F)C2=NNC(=O)C=C2 |
| InChI | 1S/C12H10F2N2O3/c1-18-10-6-7(2-4-9(10)19-12(13)14)8-3-5-11(17)16-15-8/h2-6,12H,1H3,(H,16,17) |
| InChI Key | HJMQDJPMQIHLPB-UHFFFAOYSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 12352202 |
| MSDS | msds/12984_1_101975_10_4.pdf |
| Bioactivity | Zardaverine is a newly developed dual-selective PDE3/4 inhibitor with IC50 values of 0.5 uM and 0.8 uM respectively. IC50 value: 0.5 uM (PDE3); 0.8 uM (PDE4)Target: PDE3; PDE4Zardaverine inhibited the cyclic GMP-inhibitable PDE III from human platelets and the rolipram-inhibitable PDE IV from canine trachea and human polymorphonuclear (PMN) cells with IC50-values of 0.58, 0.79 and 0.17 μM, respectively. The pyridazinone derivative affected the calmodulin-stimulated PDE I, the cyclic GMP-stimulated PDE II and the cyclic GMP-specific PDE V only marginally at concentrations up to 100μM. Zardaverine inhibits the ADP-induced aggregation of human platelets with an IC50 of 1.6 μM. This inhibition was synergistically increased by activators of adenylate cyclase such as PGE1 and forskolin. In human PMN cells, Zardaverine inhibited the zymosan-induced superoxide anion generation with an IC50 of 0.40 μM. Again, this effect was increased by activators of adenylate cyclase. Zardaverine acted in synergy with the adenylate cyclase activators prostaglandin E2 and CG 4203, a prostacyclin analog, and super-additive effects of combinations were observed. Zardaverine and dexamethasone prevent bronchial eosinophilia and neutrophilia with similar dosage of 30 microM/kg orally, suggesting that this PDE III/IV inhibitor may be useful for both, bronchorelaxation and reduction of inflammation in asthma therapy. Related Catalog Signaling Pathways >> Metabolic Enzyme/Protease >> Phosphodiesterase (PDE) Research Areas >> Inflammation/Immunology References [1]. R.T. Schermuly, H. Leuchte, H.A. Ghofrani, et al. Zardaverine and aerosolised iloprost in a model of acute respiratoryfailure. ERJ, 2003 ,22 (2): 342-347. [2]. D. Ukena, K. Rentz, C. Reiber, et al. Effects of the mixed phosphodiesterase III/IV inhibitor, zardaverine, on airway function in patients with chronic airflow obstruction. Respiratory Medicine.1995, 89 ( 6) : 441-444. [3]. Schade FU, Schudt C. The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages. European Journal of Pharmacology.1993, 230(1):9-14. Chemical & Physical Properties Density 1.4±0.1 g/cm3 Molecular Formula C12H10F2N2O3 Molecular Weight 268.216 Exact Mass 268.065948 PSA 64.21000 LogP 0.90 Index of Refraction 1.555 InChIKey HJMQDJPMQIHLPB-UHFFFAOYSA-N SMILES COc1cc(-c2ccc(=O)[nH]n2)ccc1OC(F)F Storage condition 2-8℃ |
| Use of | Properties Articles29 Name zardaverine Synonym More Synonyms Zardaverine Biological Activity Related Catalog Signaling Pathways >> Metabolic Enzyme/Protease >> Phosphodiesterase (PDE) Research Areas >> Inflammation/Immunology References [1]. R.T. Schermuly, H. Leuchte, H.A. Ghofrani, et al. Zardaverine and aerosolised iloprost in a model of acute respiratoryfailure. ERJ, 2003 ,22 (2): 342-347. [2]. D. Ukena, K. Rentz, C. Reiber, et al. Effects of the mixed phosphodiesterase III/IV inhibitor, zardaverine, on airway function in patients with chronic airflow obstruction. Respiratory Medicine.1995, 89 ( 6) : 441-444. [3]. Schade FU, Schudt C. The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages. European Journal of Pharmacology.1993, 230(1):9-14. Chemical & Physical Properties Molecular Formula C12H10F2N2O3 Exact Mass 268.065948 PSA 64.21000 Index of Refraction 1.555 InChIKey HJMQDJPMQIHLPB-UHFFFAOYSA-N Storage condition 2-8℃ |
| Transport Info | Product Name: Zardaverine |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| Yohimbine hydrochloride | 65-19-0 | 2A-9012977 |
| Zabiciprilat | 90103-92-7 | 2A-9012978 |
| Zaltoprofen | 74711-43-6 | 2A-9012981 |
| Zankiren | 138742-43-5 | 2A-9012982 |
| Zaprinast | 37762-06-4 | 2A-9012983 |
| Zatebradine | 85175-67-3 | 2A-9012985 |
| Zidapumide | 75820-08-5 | 2A-9012987 |
| Zileuton | 111406-87-2 | 2A-9012989 |
| Zimidoben | 90697-56-6 | 2A-9012990 |
| Zinc gluconate | 4468-02-4 | 2A-9012991 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS